Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in Xilio Therapeutics, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 31
- −2 vs. Q4 2023
- Shares held
- 12.5M
- −3.71M (−22.9%) vs. Q4 2023
- Total value
- $13.5M
- +$4.58M (+51.5%) vs. Q4 2023
- New holders
- 6
- 5 more added
- Sold out
- 8
- 5 more reduced
1 institution that held it in Q4 2023 haven't filed for Q1 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting XLO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 27 | $32.6M |
| Q1 2026 | 24 | $22.0M |
| Q4 2025 | 37 | $25.4M |
| Q3 2025 | 36 | $18.6M |
| Q2 2025 | 35 | $16.2M |
| Q1 2025 | 35 | $16.3M |
| Q4 2024 | 35 | $24.7M |
| Q3 2024 | 33 | $12.6M |
| Q2 2024 | 32 | $13.7M |
| Q1 2024 | 31 | $13.5M |
| Q4 2023 | 34 | $9.03M |
| Q3 2023 | 31 | $33.5M |
| Q2 2023 | 32 | $41.9M |
| Q1 2023 | 32 | $51.0M |
| Q4 2022 | 28 | $42.8M |
| Q3 2022 | 29 | $48.3M |
| Q2 2022 | 33 | $52.2M |
| Q1 2022 | 41 | $132.7M |
| Q4 2021 | 42 | $303.1M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Xilio Therapeutics, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 2,805,413 | $3.03M | 0.24% | 00.0% | Unchanged |
| FMR LLC | 1,907,671 | $2.06M | 0.00% | 00.0% | Unchanged |
| Takeda Pharmaceutical Co Ltd | 1,475,121 | $1.59M | 0.55% | 00.0% | Unchanged |
| RiverVest Venture Management LLC | 1,441,444 | $1.56M | 19.12% | 00.0% | Unchanged |
| Rock Springs Capital Management LP | 1,440,759 | $1.56M | 0.04% | 00.0% | Unchanged |
| Atlas Venture Life Science Advisors, LLC | 992,912 | $1.07M | 0.10% | −1,766,432−64.0% | Reduced |
| Vanguard Group Inc | 902,531 | $974.7K | 0.00% | 00.0% | Unchanged |
| Balyasny Asset Management LLC | 338,542 | $365.6K | 0.00% | +338,542 | New |
| Renaissance Technologies LLC | 249,446 | $269.0K | 0.00% | +39,746+19.0% | Added |
| Morgan Stanley | 221,905 | $239.7K | 0.00% | +94,640+74.4% | Added |
| FIL Ltd | 218,705 | $236.2K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 84,826 | $91.7K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 71,081 | $76.8K | 0.00% | −84,400−54.3% | Reduced |
| Millennium Management LLC | 70,198 | $75.8K | 0.00% | +39,847+131.3% | Added |
| BlackRock Inc. | 45,355 | $49.0K | 0.00% | −1,507−3.2% | Reduced |
| SevenBridge Financial Group, LLC | 31,000 | $36.6K | 0.01% | +31,000 | New |
| PFG Investments, LLC | 30,000 | $32.4K | 0.00% | +30,000 | New |
| Prelude Capital Management, LLC | 29,500 | $31.9K | 0.00% | +29,500 | New |
| FNY Investment Advisers, LLC | 27,500 | $29.0K | 0.02% | +27,500 | New |
| Northern Trust Corp | 17,798 | $19.2K | 0.00% | 00.0% | Unchanged |
| Summit Trail Advisors, LLC | 16,000 | $17.3K | 0.00% | +16,000 | New |
| State Street Corp | 15,690 | $16.9K | 0.00% | 00.0% | Unchanged |
| Dunhill Financial, LLC | 10,274 | $15.7K | 0.01% | 00.0% | Unchanged |
| Charles Schwab Investment Management Inc | 11,925 | $12.9K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 11,153 | $12.0K | 0.00% | −2,822−20.2% | Reduced |
| JPMorgan Chase & Co | 2,744 | $2.96K | 0.00% | −113−4.0% | Reduced |
| Royal Bank of Canada | 533 | $1.00K | 0.00% | +65+13.9% | Added |
| Key Financial Inc | 830 | $896 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 201 | $217 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 108 | $117 | 0.00% | +2+1.9% | Added |
| Qube Research & Technologies Ltd | 4 | $4 | 0.00% | 00.0% | Unchanged |
| Octagon Capital Advisors LP | 0 | $0 | 0.00% | −1,785,000−100.0% | Sold out |
| Artal Group S.A. | 0 | $0 | 0.00% | −450,000−100.0% | Sold out |
| Laurion Capital Management LP | 0 | $0 | 0.00% | −116,847−100.0% | Sold out |
| ArrowMark Colorado Holdings LLC | 0 | $0 | 0.00% | −83,373−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −51,419−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −10,763−100.0% | Sold out |
| Cullen/Frost Bankers, Inc. | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −11−100.0% | Sold out |
| Trustees of Columbia University in the City of New York | – | – | – | – | Not filed |